Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Dorota Kwapisz"'
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Externí odkaz:
https://doaj.org/article/f9b3368ede4449088be5b6eaae42892d
Autor:
Dorota, Kwapisz
Publikováno v:
American Journal of Clinical Oncology. 45:279-285
Trophoblast cell-surface antigen-2 (Trop-2) is a transmembrane calcium signal transducer and its overexpression is common in many types of malignant epithelial tumors, including breast cancer (BC). Sacituzumab govitecan-hziy (SG), the anti-Trop-2 ant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::31265e3a9457ad16567136e33b1687ea
https://doi.org/10.1097/coc.0000000000000919
https://doi.org/10.1097/coc.0000000000000919
Autor:
Dorota Kwapisz, Joanna Bogusławska
Publikováno v:
Biomedicine & Pharmacotherapy. 163:114851
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e4b1e26fa54f698d6c0cbdc77e11f9bd
https://doi.org/10.1016/j.biopha.2023.114851
https://doi.org/10.1016/j.biopha.2023.114851
Autor:
Dorota Kwapisz
Publikováno v:
Cancer Immunology, Immunotherapy. 70:607-617
Triple-negative breast cancer (TNBC) is defined by a lack of expression of both estrogen (ER) and progesterone (PgR) receptors as well as human epidermal growth factor receptor 2 (HER2) and is associated with poor prognosis. Moreover, the systemic tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36f1e51e69106d4ee2cc5ac6b25b0ed5
https://doi.org/10.1007/s00262-020-02736-z
https://doi.org/10.1007/s00262-020-02736-z
Autor:
Dorota Kwapisz
Publikováno v:
Handbook of Cancer and Immunology ISBN: 9783030809621
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2e8d4fa6992682ae26906833c8029c2a
https://doi.org/10.1007/978-3-030-80962-1_205-2
https://doi.org/10.1007/978-3-030-80962-1_205-2
Autor:
Dorota Kwapisz
Publikováno v:
Clinical Transplantation. 35
Immunoglobulin is built by a pair of identical heavy and a pair of identical light chains. Light chains are produced in excess compared to heavy chains. Free light chains (FLCs) are those which are not combined with heavy chains. Currently, numerous
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a3a703032f526f8b7f4ee94cbef40646
https://doi.org/10.1111/ctr.14286
https://doi.org/10.1111/ctr.14286
Autor:
Dorota Kwapisz
Publikováno v:
Breast Cancer. 26:138-146
Metastatic breast cancer (MBC) is considered as incurable. The group of patients with oligometastatic disease (a few metastatic lesions and organs involved) apparently have better prognosis. It is claimed that, these patients could be treated with cu
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b4662279491ddcd9a7cc506af7354a0
https://doi.org/10.1007/s12282-018-0921-1
https://doi.org/10.1007/s12282-018-0921-1
Autor:
Dorota Kwapisz
Publikováno v:
Breast Cancer. 25:506-516
The cyclin D-cyclin-dependent kinase (CDK) 4/6-inhibitors (CDK4/6i) induce cell cycle arrest in the G1 phase what eventually can prevent the proliferation of cancer cells. The CDK4/6i have changed the landscape of treatment options for ER-positive, H
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ff0d061eefa7dfc552ee2813215aa755
https://doi.org/10.1007/s12282-018-0864-6
https://doi.org/10.1007/s12282-018-0864-6
Autor:
Dorota Kwapisz
Publikováno v:
Breast Cancer Research and Treatment. 166:41-54
The cyclin D-cyclin dependent kinase (CDK) 4/6-inhibitor of CDK4 (INK4)-retinoblastoma (Rb) pathway plays a crucial role in cell cycle progression and its dysregulation is an important contributor to endocrine therapy resistance. CDK4/6 inhibitors tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01254b59008a7664a7baa82a1aeb0d2a
https://doi.org/10.1007/s10549-017-4385-3
https://doi.org/10.1007/s10549-017-4385-3
Autor:
Dorota Kwapisz
Specific mutations in epidermal growth factor receptor (EGFR) gene are predictive for response to the EGFR tyrosine kinase inhibitors (TKIs) in non-small cell lung cancer patients (NSCLC). According to international guidelines, the molecular testing
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::21a20e558a8aa0cb1a3e0ba69406ba69
https://europepmc.org/articles/PMC5326656/
https://europepmc.org/articles/PMC5326656/